Andere talen ZYUS Life Sciences Corporation

Aandelen

ZYUS

CA9899601095

Beurs gesloten - Toronto S.E. Andere beurzen 15:34:16 09-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,17 ^CAD	-1,68%		+17,00%	+30,00%

07/05	ZYUS Life Sciences Corporation rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
01/02	Zyus benoemt Dr. Hance Clarke tot lid van de klinische adviescommissie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ZYUS Announces Completion of Its Annual Filings	08/05
INSERTING and REPLACING ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9	08/05
ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	07/05
ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	23/04
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management	23/04
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	05/03
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	20/02
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	20/02
ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke	02/02
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee	01/02
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee	01/02
ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research	10/01
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Management	06/12
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care	05/12
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management	05/12
ZYUS Life Sciences Corporation Reports Q3 2023 Results	30/11
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/11
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin Softgels	22/11
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels	21/11
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels	21/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ZYUS Life Sciences Corporation

Aandelen

ZYUS

CA9899601095

Andere talen

Filters